Elanco’s Credelio Quattro tablets granted FDA conditional approval

Elanco (ELAN) has received conditional approval from the FDA for Credelio Quattro-CA1 – lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets – for the treatment of infestations caused by New World screwworm larvae, or myiasis, in dogs. This is the first FDA conditional approval for a companion animal product to treat New World screwworm. Credelio Quattro-CA1 now joins Credelio – lotilaner – and Credelio CAT – lotilaner – on the list of companion animal treatment options for New World screwworm, with these other products recently receiving FDA Emergency Use Authorization for the treatment of New World screwworm infestations in dogs and cats, respectively. According to the FDA, a conditionally approved animal drug has been shown to be safe and has a reasonable expectation of effectiveness. Veterinarians and consumers will see new product labeling in 2026 that reflects the conditions of use for both Credelio Quattro and Credelio Quattro-CA1 on the same packaging. According to USDA, there have been 14 cases of New World screwworm within 400 miles of the U.S.-Mexico border, all of them related to cattle movement.